Discoveries

The McGowan Institute for Regenerative Medicine (MIRM) at the University of Pittsburgh, established in 1992 as the McGowan Center for Artificial Organ Development and expanded in 2001 to encompass broader regenerative strategies, has been a pioneer in addressing tissue and organ insufficiency through innovative research. Funded initially by philanthropist William G. McGowan following his heart transplant at UPMC, the Institute integrates expertise from over 250 affiliated faculty across medicine, engineering, and biology. Its mission focuses on developing therapies via tissue engineering, cellular therapies, and medical devices, with a strong emphasis on clinical translation. Over the past three decades, MIRM has generated over 1,600 patents worldwide, licensed 185 technologies, and spun out more than 30 companies, impacting millions of patients. Key discoveries have advanced from artificial organ prototypes in the 1990s to sophisticated biomaterials and gene-editing tools in the 2020s. These breakthroughs are categorized below by the Institute’s core research pillars: Medical Devices and Artificial Organs, Tissue Engineering and Biomaterials, and Cellular Therapies. The top five discoveries, selected for their scientific impact, clinical potential, and translational success, exemplify MIRM’s evolution.

Medical Devices and Artificial Organs

This pillar, rooted in the Institute’s founding focus, emphasizes biohybrid systems and implantable devices to support or replace failing organs. Early developments in the 1990s targeted circulatory and respiratory support, evolving into widely adopted technologies.

1. Ventricular Assist Devices (VADs) and Circulatory Support Systems (1990s–2000s): MIRM researchers contributed to the design and refinement of mechanical circulatory support devices, including the most implanted VAD globally, used for heart failure patients awaiting transplants or as destination therapy. These systems, such as biohybrid pumps integrating synthetic materials with biological interfaces, addressed congenital defects and post-myocardial infarction conditions. By the early 2000s, these innovations reduced mortality rates in advanced heart failure by providing bridge-to-transplant support, with over 20,000 annual implants worldwide today. This work laid the foundation for pediatric-specific devices and extracorporeal lung assist systems, demonstrating long-term durability and biocompatibility in clinical trials. Impact includes improved survival for neonatal and adult patients, with ongoing refinements for fully implantable, wireless systems.

2. Biodegradable Nerve Guides for Peripheral Nerve Regeneration (2010s–2020s): Led by Kacey Marra, PhD, this breakthrough involves a polycaprolactone-based polymer tube filled with glial cell line-derived neurotrophic factor (GDNF), released over months to bridge large nerve gaps (up to 5 cm). Preclinical studies in nonhuman primates restored approximately 80% of fine motor function in median nerve injuries, outperforming autografts in some metrics by avoiding donor site morbidity. Developed through FDA-approved materials, the guide promotes axonal regrowth without stem cells or donor tissue, with applications in facial nerve repair and volumetric muscle loss. A spinout company, AxoMax Technologies, is advancing this toward first-in-human trials, potentially revolutionizing treatment for traumatic nerve injuries affecting millions annually.

Tissue Engineering and Biomaterials

MIRM’s biomaterials research, prominent since the 2000s, leverages natural scaffolds to induce constructive tissue remodeling, with applications in wound healing and organ reconstruction.

3. Extracellular Matrix (ECM) Bioscaffolds (2000s–Present): Pioneered by Stephen Badylak, DVM, PhD, MD, these decellularized mammalian ECM scaffolds serve as inductive templates for functional tissue reconstruction. Derived from sources like porcine urinary bladder, they recruit progenitor cells, modulate immune responses, and promote site-specific remodeling in musculoskeletal, esophageal, and neural tissues. Over 13 million patients have benefited from ECM-based therapies, with forms including powders, sheets, and hydrogels entering clinical trials for conditions like esophageal cancer and volumetric muscle loss. Key milestones include FDA clearances in the 2010s and the establishment of ECM Therapeutics in 2019 for scalable manufacturing. This discovery has shifted paradigms from inert implants to bioactive materials that harness endogenous repair mechanisms.

4. Matrix-Bound Nanovesicles (MBVs) (2016–Present): Discovered in the Badylak lab as embedded components within ECM scaffolds, MBVs are lipid-enclosed vesicles (30–150 nm) containing microRNAs and proteins that recapitulate ECM’s immunomodulatory effects. They shift macrophages toward anti-inflammatory (M2) phenotypes, equaling methotrexate’s efficacy in preclinical rheumatoid arthritis models and preventing ischemia-induced retinal ganglion cell death. Unlike free extracellular vesicles, MBVs are matrix-tethered, enabling targeted delivery in bioscaffolds for wound healing and neuroblastoma modulation. This 2016 finding, published in Science Advances, has led to patents and applications in anti-fibrotic therapies, demonstrating pro-healing without immunosuppression in vaccinated models.

Cellular Therapies
Emerging in the 2000s with stem cell integration, this area focuses on reprogramming and gene delivery for in vivo tissue repair, accelerating translation through nanotechnology.

5. Tissue Nanotransfection (TNT) Technology (2010s–2020s): Integrated into MIRM under Director Chandan Sen, PhD (appointed 2023), TNT uses silicon nanochips for non-viral, in vivo gene delivery via nanoelectroporation, reprogramming cells in under a second. It converts skin fibroblasts into vascular or neural cells, rescuing perfusion in diabetic ischemic wounds through CRISPR-dCas9-mediated epigenetic editing of PLCγ2 promoters. Preclinical studies since 2017 show enhanced VEGF efficacy and potential for neural repair in austere environments. As a point-of-care tool, TNT addresses chronic wounds affecting 6.5 million U.S. patients annually, with ongoing trials for fungal/viral infections and space biomedicine applications via NASA partnerships.

These discoveries underscore MIRM’s interdisciplinary approach, yielding tangible clinical outcomes while fostering innovation ecosystems. Future directions include AI integration and space-based biomanufacturing, poised to further transform regenerative medicine.